PDCD1 and cancer: More importantly, the combination of 4-1BB agonistic antibody and anti-PD1 therapy contributed to the better control of cancers and the further promotion of proliferative function, cytotoxicity and downregulation expression of TIM3 and LAG3 in TEXs (Table 1) (18, 46, 50, 51).